Mind Medicine (MindMed) Inc (MNMD)

[Kpriddy1]

Mind Med Webinar w/Kevin O’Leary and JR Rahn Highlights:
- Prior to investing, O’Leary’s team extensively look into Mind Med prior to investing. One of Mr. O’Leary’s employees liked the company so much that he got a loan from O’Leary for $15 million to invest. O’Leary then went and invested more because he said “I can’t have one of my employees investing more than me”.
- Absolutely no chance of recreational involvement. O’Leary made that clear so that institutional investors will be able to invest. Their goal is to achieve FDA approval and/or FDA fast-track approval through their clinical trials.
- No chance of liquidating shareholders in order to acquire any companies.
- They have a patent on a drug that neutralizes the effects of LSD.
- They are targeting microdosing LSD towards ADHD ($16 billion dollar a year industry) and anxiety/depression. JR Rahn said he got the idea to further research the applications of LSD when he was in silicon valley and had a lot of friends with ADHD who would microdose to treat and control their symptoms.
- They are targeting the drug 18-MC (derivative of ibogaine) to treat drug addiction (primarily aimed at treating opioid addiction) and alcohol abuse disorder. The application towards the treatment of opioid abuse disorder is where JR Rahn believes they may get Fast Track FDA approval if they see results because there are very few medications right now effective at treating opioid use disorder.

Please add more if you can remember things that I left out. I was unable to listen to the entire webinar.